1、 b%?_S T: 100730SD S SxD Sv xD_ S %?_ZE#SZ鄢盛恺 林其燧 h L, %?(HDL-C) “(AS)M1。 SFraminghamA U, HDL-C h 0. 026mmol/L( 1mg/dl),3h(CHD)? 3B|9F2% 3%。 “ - “5 XWHDL-C/TCHDBy S。HDL-C 0. 91mmol/L (35 mg/dl) CHD1By ,7HDL-C 1. 55 mmol/L(60 mg/dl)$ By0, 1,2。T I SSE%?9(NCEP)1q#D ,HDL-C_ZE#S5TBe 。B、HDL 3 (CM)、 (VLDL)
2、 (LDL)M1, (HDL) Kv(d= 1. 063 1. 210 kg/L)。 Fs(Pro)、(PL)、%?(chol)(TG)50%、 25%、 20%5%。HDLPro1 (apo)AIAII;chol9%?(TC)25% 35% ,%?(CE) %?(FC)13 1。HDL VYV s8T,|FcholM#) , H% |LDL-C,Echol C,#HDL$ ASy03。=、HDL-C_ZE cchol,yNAV s HDL。s HDLZE E、 V rE、 fE、E#E。 “5 L iKW E。 S +HDL-CZE,y eL、 y , ?1s,X W1。1. IZE: S%
3、h e(CDC)HDL-C IZE E,9NCEPwi4。Es : (1) (40 000r/min, 18. 5l H)“ (d) 1. 006 kg/LcTG(CM、VLDL)。( 2)/A -MnCl2E( Hep-Mn2+E) (1 500g, 30s),“ capoBLDL、 Lp(a)。(3) bAcholc ,ZECDC IZE( ALBKE)。NE1 #HDL-C_ZE N,9 S=W $。 , T O,S v(5 ml), HW,B Li 4 7Z, av? S1 。CDC%? IZE L i (Cholesterol ReferenceMethod Laboratory N
4、etwork, CRMLN) B“1 ZE”TMCDC IZE aZE。NE n5 ; (DS50,s0 5)T4(DS50-Mg2+ ), ,“ capoBCM、 VLDL、 IDL、 LDLLp(a) ; bAHDL%?ALBKE。ZEX L i$-% N#S,MCDC IZE7,Xve5。?ZCDC IZET V1 e IZE|HDL-CS? L i 7Z。2.E:4| 0, (PTA)、DS、 (Hep)d 0 8 Y=?(PEG) t N 0( Mg2+ 、 Ca2+ 、Mn2+ ) ? P“HDLcapoB。 Es b#。HDLchol E(CHOD-PAP)。N ZE Te,L
5、! On , a Y L i。$NCEPwi?ZE5。* E Hep-Mn2+E, sTG , P b$, OMn2+ E19D_1998 M121 1 chol,# “ -X。 CDC-NHLBI(S kA )Ci1HDL-CCHDB h “5 oNE,#NCEPyp =。PEG6000-Mg2+Er q,CDC IZE zB, ,SCX 。Warnick6wiDS50-Mg2+E, s HDL z+s,yS= k4 7K 。DS500-Mg2+E(DS500,s0 50)HDL-CT,| b411 1,VLDL vv,4 _ 7。PTA-Mg2+E Echol, Ok4,TG b9 ? ,
6、 “ - “5L iKZE, S50% k4NE。Demacker86E 1 ,TV PTA-Mg2+E910. 6% ,NCEP1 p。PTA-Mg2+ET V L,n ,a?。D_9S =wiNE,i W%_9。E sTGY,capoB R y? 7HDL-CL9。 XN , SReference Diagnostics wBHDSE_ k4。 B4 bS1 5BS, |SbH ,dHDL R y$H, ? y$H (),7HDL R s ( b)。NVe , ,HDL #capoBR C。T , sTG ,1.dDS50-Mg2+E HWvv ,gBN10。3.E:BHq/,s0vl#
7、A ,# %M qg。 lHDLs0_ %M q, V|HDLVLDL、 LDLus 7。Helena X 7? VREP y 1N PHDL-C_ k4, : b(1l) j (400V, 15s),|chol k4 ( V ,BHW( 10s)10%bZ %, | K。570 nmo/1 V HDL-Csc 。 H| bTC ,5 V p bHDL-C。NEPTA-Mg2+E zM1, VTGS_,9 NE , “ - “5。4.E:EHDL-C|S4) , bAZ VEEchol。 Kv ?1s, av? h “5v S “ H_。S+ MM? 7?+E, VN 1, “5# H、 y
8、、 HDL-C#ST4 Hq。(1)PEG/ F8UE:Kakuyama111994 MPEG FapoB、FapoC F8UdHDL, EHDL-C1sZE。 Interna-tional Reagents X V 1_ k4。V 4 k4: iPEG4000,UCM、 VLDL、 LDL。+s FapoB、apoC F8, PCM、VLDLLDL 。 k4,_ %?(HDL-C)。 k4, Q capoB, ;。Nauck12PEG/ F8UE “d N,EPTA-Mg2+E zM1(r=0. 970),9CV2. 4% 8. 4% ,LS Vr1 500 mg/L,Kl VK 30 mg
9、/L。E FTG? ,TG20g/L PT92%。 PTA97i PT 。NEs, T_ 1, k4+sF87 P (PTA-Mg2+E20), O1 VF4 k4 3sNsF 4 k4,y7K “5, “ - Hitachi 9111 3sN。(2)4E: V 4#| 0, Q4,HDL-C。BQ,F |0s V 4(gQ4),LDL、VLDLCM5| 0/ “,Q4LDL、VLDLCM y T ,# “ R V 7。 HHDLV 9 Q4, T , V I。=Q,%? k4B F HDL R T v T V V 4(gQ4),Q4HDL V +sT V V Q4,V7 k4Q,rs HDL
10、-C20 Chin JMed Lab Sci, January1998, Vol21, No. 1 “。1995 M B0 T(Daiichi)wB V1_ k4, k4 k4 , BnM ,YrT。1996 M/ Mw=A8k4, k4, a 1 3sN。 SGenzyme Diagnostics k4N-genousTMHDL-Cg N ZE。NE S (3l b), ( =、 WCV ( 3% ),PTA-Mg2+EM1z(r= 0. 987),LS Vr1 500 mg/L, l q90% 110%。、Vit CY, Yip13,14。Huang14?C4E_HDL-C+s, V ?B
11、QdHDL U7,7 P k4 CM、VLDLLDL%? 3Q, PTL9。yN, “5WwNE -,An“dS4 +s。( 3)PEG eE:Sugiuchi151995 MPEG e %?Q4,- ; Mg2+# DST/,5s bHDL-CZE。PEG6000 ? %? (CEH)%? (CHOD)M,M PEG-CEHPEG-CHODbT4, GQLDLVLDLCM HDL。7- ; ?KCM、VLDLR ,V7E bT,TMg2+ i1。yN,Mg2+# DSi -4/, V_HDL-C。 x( Kyowa)、SCentronic GmbH BoehringerMannheim#SR
12、ANDOX XsYV1_ k4。NE b (4l),LS z(r1 500 mg/L), ( =、 WCV ( 3% ), l q99% 103% ,i、 _TY l, sVit C、 ,PTA-Mg2+E zM1(r= 0. 975)。 PEG eETG(30 000 mg/L) HPEGM ?VLDLQ,7 PT ,9 NCEP V sS =10。T ,PEG eE+s Z 4E14,7 a? L i。、HDL-C_SHDL-C s? “,X “5 j。V , HDL-C V LDL-C9 , Tl V CHDB9p。yN,A 7Z_ST T V L。HDL-C_S1ZE 4、S e !#
13、SZ L 。1.S “S: CDC-NHLBISHDL-C_ V sK “S ?。1 p_ CDC I(RV) 10% =,l1. 03 mmol/L(40 mg/dl)、 1. 03 1. 55 mmol/L( 40 60 mg/dl)、v1. 55mmol/dl(60mg/dl) iS =, HDL-C_Kv ssY0. 065 mmol/L( 2. 5 mg/dl)、 0. 078 mmol/L( 3. 0mg/dl)、 0. 090 mmol/L( 3. 5 mg/dl)。NCEP “ - “S922%; 1 pHDL-C1. 09mmol/L( 42 mg/dl) H, CV 6%;
14、 HDL-C 1. 09mmol/L(42 mg/dl) H,s0. 065 mmol/L(2. 5mg/dl)。 1 p (bias) 10% (CDC IZE1 )。1998 M “S913%; 1 pHDL-C 1. 09 mmol/L(42 mg/dl) H,CV4%; HDL-C 1. 09 mmol/L H,s 0. 044mmol/L(1. 7mg/dl)。 1 p 5% 5。2.S e : HDL-CST n51y B*Z, N! a IS。 -S= X zTCs“d# V LS I,HDL-CST7/ Hq。SX SS/ (NIST)%?B SRM 911bM%?S# IZE
15、%? b16。CAPYV L,r(matrix effects)YEHDL-C。 Bt_N ZEL?C,r AY_L,7 OY。yN,1 pS e srYYKl, aHDL-CZEn、S e, ?_ , HW,7 O ?S=S = iWN。HDL R ,FsapoBM, P! aHDL-CS 4。“ -E4n e ,gA8,7 OY .。CDCBb bT IHDL-CS,k。 d 7?1_ZE S4 ZL,n e 4 1 p。BZ 1 1 p, 6BZ “521D_1998 M121 1 ? H “N n e。9 HDL-C 5B。3.ZE5: “ -HDL-C%ZE#B) I , PHDL-
16、CST 4v。NCEP HDL-C_ “d$,iwi HDL-CZ。wiCDC E IZE,E?ZE。S “S, h s -( sk!、S“、) i),_Vi5( hlrY、4+s e)# iW 94 Bt 81 pyp。 S1996 M “5 iW l,S = “ - EHDL-C, PTA-Mg2+E n( 61. 8% ), QPEG6000E(24. 3% )。 - s Hq?S, “5S7 b_E r。 H!S = b,_VS。+1_ZE“d N,9B )。 ID1 Wilson PW, Abbott RD, CastelliWP. High densitylipoproteinch
17、olesteroland mortality. The Framingham Heart Study. Arte-riosclerosis, 1988, 8: 737-741.2 National Cholesterol Education Program. Second report of theexpert panel on detection, evaluation, and treatment of highbloodcholesterolinadults (AdultTreatment Panel ). Circula-tion, 1994, 89: 1330-1445.3 Badi
18、mon JJ, Fuster V, Badimon L. The role of high densitylipoprotins in the regression of atherosclerosis. Circulation,1992, 86: -86-94.4 WiebeDA, Warnick GR. Measurementofhigh-density lipopro-tein cholesterol. In: Rifai N, Warnick GR, eds. Laboratorymeasurementof lipids, lipoproteins and apolipoprotein
19、s. Wash-ington, DC: AACC Press, 1994: 91-105.5 Warnick GR, Wood PD. National Cholesterol Education Pro-gram recommendations for measurementofhigh-densitylipopro-tein cholesterol: executive summary. Clin Chem, 1995, 41:1427-1433.6 Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+precipitation
20、procedure for quantitation of high-density lipopro-tein cholesterol. Clin Chem, 1982, 28: 1379-1388.7 , 2, ,. ; 500- E b %?.D_,1996,19: 22-24.8 Demacker PNM, Hessels M, Toenhake-Dijkstra H, etal. Pre-cipitation methods for high-density lipoprotein cholesterol mea-surementcompared, andfinalevaluation
21、under routineoperatingconditions ofa method with alow sample-to-reagent ratio. ClinChem, 1997, 43: 663-668.9D_wiZE. 、 b %?E().D_,1995, 18: 311-312.10 Harris N, Galpchian V, Rifai N. Three routine methods formeasuring high-densitylipoprotein cholesterolcomparedwith thereferencemethod. Clin Chem, 1996
22、, 42: 738-743.11 Kakuyama T, Kimura S, HashiguchiY. Fullyautomated deter-minationof HDL-cholesterolfromhumanserum with Hitachi 911Abstract. Clin Chem, 1994, 40: 1104-1109.12 Nauck M, Marz W, Haas B, et al. Homogeneous assay for di-rect determination of high-density lipoprotein cholesterolevalu-ated.
23、 Clin Chem, 1996, 42: 424-429.13 Harris N, Galpchian V, Thomas J, etal. Threegenerations ofhigh-density lipoproteincholesterolassays compared with ultra-centrifugation/dextran sulfate-Mg2+ method. Clin Chem, 1997,43: 816-823.14 Huang YC, Kao JT, Tsai KS. Evaluation of two homogeneousmethods formeasu
24、ring high-densitylipoproteincholesterol. ClinChem, 1997, 43: 1048-1055.15 Sugiuchi H, UjiY, Okabe H, etal. Directmeasurementofhigh-density lipoproteincholesterolinserumwithpolyethyleneglycol-modifiedenzymesandsulfated-cyclodextrin. Clin Chem, 1995,41: 717-723.16 rL.4_ in.D_,1994,17: 5-6.( l: 1997-09
25、-14 : 1997-10-27)(I :f )h “5_/ )、 Z、z 7 VrD K SDADS=“v1997 M8、 Z、sY 3、 、 3、 fZ5 )。pz 7 “S =K5_/ ZE_,i O W 5_N 。NQp$ h S =1EF, 3Z , DadeS=“vMicroscan Sam morishina53、 * q、 q、 Bq、 。 /Z : Th ;5 3、 q、W H q、 q、;Y q、y q。 3、 fZ : q、 +) q、u 3 q。 = 1997 M SASMp#ICCp ; “5 3G; L i_ “5; 4 3sN; 3S:Z;S “5。22 Chin JMed Lab Sci, January1998, Vol21, No. 1
